Robert M. Califf

Professor of Medicine
Donald F. Fortin, M.D. Professor of Cardiology, in the School of Medicine
Member of the Duke Clinical Research Institute
Campus mail 100 Trent Drive, Suite401, Davison Building, Durham, NC 27710
Phone (919) 668-9222
Email address

Robert Califf, MD MACC, is the Donald F. Fortin, MD, Professor of Cardiology. He is also Professor of Medicine in the Division of Cardiology and remains a practicing cardiologist. Dr. Califf was the Commissioner of Food and Drugs in 2016-2017 and  Deputy Commissioner for Medical Products and Tobacco from February 2015 until his appointment as Commissioner in February 2016. Prior to joining the FDA, Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.

Dr. Califf is a Member of the National Academy of Medicine (formerly known as the Institute of Medicine (IOM)) in 2016, one of the highest honors in the fields of health and medicine. Dr. Califf has served on numerous IOM committees, and he has served as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board's Subcommittee on Science and Technology. Dr. Califf has also served on the Board of Scientific Counselors for the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging.

He has led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by the FDA and Duke. He also served as the principal investigator for Duke's Clinical and Translational Science Award and the NIH Health Care Systems Research Collaboratory coordinating center and co-PI of the Patient Centered Outcomes Research Institute Network.

Associated Faculty Labs


Harrell, F. E., R. M. Califf, D. B. Pryor, K. L. Lee, and R. A. Rosati. “Evaluating the yield of medical tests..” Jama 247, no. 18 (May 14, 1982): 2543–46.


Williams, R. S., A. G. Wallace, M. C. Hindman, R. M. Califf, J. A. Blumenthal, F. Paul Koisch, M. C. Morey, et al. “Duke university’s preventive approach to cardiology-DUPAC.” Journal of Cardiac Rehabilitation 2, no. 6 (January 1, 1982): 509–14.


Rosati, R. A., K. L. Lee, and R. M. Califf. “Problem and advantages of an observational data base approach to evaluating the effect of therapy on outcome.” Circulation 65, no. 7 II (1982).


Califf, R. M., and R. A. Rosati. “The doctor and the computer..” West J Med 135, no. 4 (October 1981): 321–23.


Califf, R. M., J. M. Burks, V. S. Behar, J. R. Margolis, and G. S. Wagner. “Relationships among ventricular arrhythmias, coronary artery disease, and angiographic and electrocardiographic indicators of myocardial fibrosis..” Circulation 57, no. 4 (April 1978): 725–32.


Abel, R. M. “Coronary atherectomy versus angioplasty..” N Engl J Med 329, no. 25 (December 16, 1993): 1891–92.


Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, H., F. Van De Werf, J. Adgey, D. Ardissino, P. W. Armstrong, P. Aylward, G. Barbash, et al. “Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial..” Lancet 354, no. 9180 (August 28, 1999): 716–22.

Full Text